Newsletter

000250 - Samchundang Pharm

000250 Summary
Biopharma
Stock Price & Overview
₩157,000 +1,600 (+1.03%) Close · Sep 4, 2026 KST
KOSDAQ | ₩KRW | Close: ₩157,000  ≈ US$112  ·  Market cap ₩3.7tn (≈ $2.6bn)

000250 Quarterly Results

Quarter ₩bnRevenueYoYOperating incomeMarginYoYNet incomeEPS
2026 Q270.7+24.3%3.44.9%—6.2₩264
2026 Q164.9+28.2%5.48.4%+692.4%6.9₩294
2025 Q466.3+20.1%5.48.2%—7.9₩337
2025 Q358.0+10.8%3.45.9%—4.5₩190
2025 Q256.9+3.7%-1.1-1.9%-150.5%-1.6₩-69
2025 Q150.6+4.5%0.71.4%-63.1%1.3₩54
2024 Q455.2—-0.5-1.0%—-8.9₩-381
2024 Q352.4—-0.8-1.6%—-0.3₩-12
Three-month figures from DART consolidated statements. Q4 is the annual figure less the nine-month cumulative. EPS is net income over today's share count, so buybacks and issuance move earlier quarters. YoY compares with the same quarter a year earlier and is blank when that quarter was a loss.

000250 Annual Results

Full statements »
Fiscal year ₩bnRevenueYoYOperating incomeMarginYoYNet incomeEPS
FY2025231.8+9.9%8.53.7%+220.5%12.0₩513
FY2024210.9+9.5%2.61.3%-72.4%-5.1₩-216
FY2023192.7+8.6%9.65.0%-21.8%-4.2₩-179
FY2022177.3+6.0%12.26.9%—8.8₩377
FY2021167.3+0.2%-15.3-9.1%-376.9%-10.4₩-442
FY2020166.9-10.6%5.53.3%-78.1%7.5₩320

000250 Next Report

The latest quarter on file is 2026 Q2. The next one, the Q3 2026 report covering the period to Sep 30, 2026, is due on DART by Nov 14, 2026 — Korean issuers must file quarterly and half-year reports within 45 days of period end and the annual report within 90 days.

Large issuers usually publish preliminary consolidated figures (잠정실적, a fair-disclosure filing with revenue and operating profit only) in the first weeks after the period ends, ahead of the full report. kstock does not know a company's chosen release date; when the preliminary filing arrives it appears under Filings and on this page.

000250 Earnings Filings

All filings »
DART

Half-Year Report

Periodic08/14/26title translated
DART

Annual Report

Periodic06/04/26title translated
DART

Quarterly Report

Periodic05/15/26title translated

How Korean earnings differ from US earnings

  • No quarterly guidance culture. Most KRX companies give no EPS or revenue guidance; the preliminary filing is the first number the market sees, and there is no consensus beat/miss ritual built around it.
  • Preliminary first, then the report. The 잠정실적 filing carries revenue and operating profit; net income and the balance sheet come with the full report weeks later.
  • Consolidated is the headline. Korean companies report consolidated (K-IFRS) and separate (parent-only) figures; kstock uses consolidated unless the page says otherwise.
  • Fiscal years end in December for almost every listed company, so Q4 is derived: the annual figure less the nine-month cumulative.

Similar to 000250

SymbolLast Price
000100Yuhan Corporation₩81,400
+0.0%
028300HLB Co., Ltd.₩33,750
+2.9%
298380ABL Bio Inc.₩71,400
+5.6%
087010Peptron, Inc.₩157,300
+7.3%
141080LigaChem Biosciences Inc.₩92,000
+4.2%
145020Hugel, Inc.₩244,000
+1.5%
302440SK Bioscience Co., Ltd.₩37,900
+0.4%
009420Hanall Biopharma Co., Ltd.₩54,700
+1.5%
310210Voronoi, Inc.₩153,000
+3.9%
214370Caregen Co., Ltd.₩44,500
+1.5%
Compare all 48 in Biopharma

What a US investor should know

  • Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
  • Daily limitKorean stocks can move at most ±30% in a session before trading halts.
  • Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
  • ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.